Daniel Rotroff, PhD, Lerner Research Institute, Cleveland, OH, shares the preliminary results of Genetics and Inflammatory Markers for CIPN Study (GENIE) study designed for the development of biomarkers predict chemotherapy-induced peripheral neuropathy (CIPN) among early stage breast cancer patients receiving taxane therapy. The preliminary model is currently demonstrating 84% accuracy in predicting which patients will develop moderate to severe CIPN. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.